Advertisement
U.S. markets open in 6 hours 15 minutes
  • S&P Futures

    5,046.75
    +50.50 (+1.01%)
     
  • Dow Futures

    38,792.00
    +115.00 (+0.30%)
     
  • Nasdaq Futures

    17,861.25
    +324.50 (+1.85%)
     
  • Russell 2000 Futures

    2,014.20
    +13.70 (+0.68%)
     
  • Crude Oil

    78.17
    +0.26 (+0.33%)
     
  • Gold

    2,042.20
    +7.90 (+0.39%)
     
  • Silver

    23.11
    +0.24 (+1.03%)
     
  • EUR/USD

    1.0864
    +0.0041 (+0.38%)
     
  • 10-Yr Bond

    4.3250
    0.0000 (0.00%)
     
  • Vix

    15.34
    0.00 (0.00%)
     
  • dólar/libra

    1.2687
    +0.0049 (+0.39%)
     
  • USD/JPY

    150.0550
    -0.2530 (-0.17%)
     
  • Bitcoin USD

    51,837.00
    +218.75 (+0.42%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,667.47
    +4.96 (+0.06%)
     
  • Nikkei 225

    39,098.68
    +836.52 (+2.19%)
     

Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023

NobleCon is the preeminent showcase of small and microcap companies

NEW YORK, Nov. 10, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL.

(PRNewsfoto/Hoth Therapeutics Inc.)
(PRNewsfoto/Hoth Therapeutics Inc.)

To learn more about NobleCon and registration to attend or scheduling a one-on-one meeting with management please visit  https://noblecon19.com/#companies.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-to-present-at-noblecons-19th-annual-emerging-growth-investor-conference-december-3-5-2023-301984402.html

SOURCE Hoth Therapeutics, Inc.

Advertisement